By studying the immune cell infiltration, immune-related gene expression profiles and immune-related biological pathways in HNSCC patients, Zhu and colleagues found that combining anti-VEGF signaling pathway drugs with immunotherapy may be a new therapeutic direction [20]. Here, VEGFA is linked to head and neck squamous cell carcinoma.